Association between components of the insulin-like growth factor system and endometrial cancer risk

Oncology

Volumn 67, Issue 1, 2004, Pages 54-59

  Augustina, Livia S A ^a,b   Dal Maso, Luigino ^a   Franceschi, Silvia ^c   Talamini, Renato ^a   Kendall, Cyril W C ^b   Jenkins, David J A ^b   Vidgen, Ed ^b   La Vecchia, Carlo ^d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Case control study; Endometrial cancer; Insulin like growth factor system; Obesity

Indexed keywords

IGF BINDING PROTEIN 1; IGF BINDING PROTEIN 3; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CELL PROLIFERATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOMETRIUM CANCER; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; INTERVIEW; ITALY; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

ADULT; AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; ITALY; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SOMATOMEDINS;

EID: 5644268978     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080286     Document Type: Article

References (36)

1. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S: The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
2. Parazzini F, La Vecchia C, Negri E, Riboldi GL, Surace M, Benzi G, Maina A, Chiaffarino F: Diabetes and endometrial cancer: An Italian case-control study. Int J Cancer 1999;81:539-542.
3. Grady D, Ernster VL: Endometrial cancer; in Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention. Oxford, Oxford University, 1996, pp 1058-1089.
4. Kaaks R, Lukanova A, Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-1543.
5. Augustin LS, Gallus S, Bosetti C, Levi F, Negri E, Franceschi S, Dal Maso L, Jenkins DJ, Kendall CW, La Vecchia C: Glycemic index and glycemic load in endometrial cancer. Int J Cancer 2003;105:404-407.
6. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
7. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et al: Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-2512.
8. Yee D, Lee AV: Crosstalk between the insulinlike growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107-115.
9. Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M, Yu H: Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001;91:736-739.
10. Daughaday WH, Rotwein P: Insulin like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989;10:68-91.
11. Seppala M, Koistinen R, Rutanen E-M: Uterine endocrinology and paracrinology: Insulinlike growth factor binding protein-1 and placental protein 14 revisited. Hum Reprod 1994;9:917-925.
12. Rutanen EM: Insulin-like growth factors in endometrial function. Gynecol Endocrinol 1998;12:399-406.
13. Rutanen EM, Pekonen F, Makinen T: Soluble 34k binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: Evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab 1988;66:173-180.
14. Bermont L, Fauconnet S, Lamielle F, Adessi GL: Cell-associated insulin-like growth factorbinding proteins inhibit insulin-like growth factor-I-induced endometrial cancer cell proliferation. Cell Mol Biol 2000;46:1173-1182.
15. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR: Phosphorylation of insulinlike growth factor (IGF)-binding protein 1 in cell culture and in vivo: Effects on affinity for IGF-I. Proc Natl Acad Sci USA 1991;88:7481-7485.
16. Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ: Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 2003;14:65-74.
17. Cohen P: Serum insulin-like growth factor-I levels and prostate cancer risk - interpreting the evidence. J Natl Cancer Inst 1998;90:876-879.
18. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor I and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90:911-915.
19. Pollak M, Beamer W, Zhang JC: Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998-1999;17:383-390.
20. Signorello LB, Brismar K, Bergstrom R, Andersson S-O, Wolk A, Trichopoulos D, Adami HO: Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst 1999;91:1965-1967.
21. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299.
22. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-625.
23. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999;91:151-156.
24. Mathur SP, Mathur RS, Young RC: Cervical epidermal growth factor receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol 2000;44:222-230.
25. Petridou E, Dessypris N, Spanos E, Mantzoros C, Skalkidou A, Kalmanti M, Koliouskas D, Kosmidis H, Panagiotou JP, Piperopoulou F, Tzortzatou F, Trichopoulos D: Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int J Cancer 1999;80:494-496.
26. Ayabe T, Tsutsumi O, Sakai H, Yoshihawa H, Yano T, Kurimoto F, Taketani Y: Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-I in postmenopausal women with endometrial cancer. Endocr J 1997;44:419-424.
27. Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH: Relationship between carbohydrate metabolism and serum insulin-like growth factor system in post-menopausal women: Comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab 1993;77:199-204.
28. Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E, Trichopoulos D: Endometrial cancer and the IGF system: A case-control study in Greece. Oncology 2003;64:341-345.
29. Breslow NE, Day NE: Statistical Methods in Cancer Research. Lyon, International Agency for Research on Cancer, 1980, vol 1:The Analysis of Case-Control Studies, IARC Scientific Publication 32.
30. Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R: Serum levels of insulin-like growth factor-1, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer 2003;89:1697-1704.
31. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R: Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2, and -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-268.
32. Khandwala HM, McCutcheon IE, Flyvbejerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-244.
33. Maiorano E, Loverro G, Viale G, Giannini T, Napoli A, Perlino E: Insulin-like growth factor-I expression in normal and diseased endometrium. Int J Cancer 1999;80:188-193.
34. Franceschi S, Barbone F, Negri E, Decarli A, Ferraroni M, Filiberti R, Giacosa A, Gnagnarella P, Nanni O, Salvini S, et al: Reproducibility of an Italian food frequency questionnaire for cancer studies. Results for specific nutrients. Ann Epidemiol 1995;5:69-75.
35. Brismar K, Hilding A, Lindgren B: Regulation of IGFBP-1 in humans. Prog Growth Factor Res 1995;6:449-456.
36. Weaver JU, Holly JM, Kopelman PG, Noonan K, Giadom CG, White N, Virdee S, Wass JA: Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. Clin Endocrinol (Oxf) 1990;33:415-422.